The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The West Africa generic drug market is expected to exhibit a CAGR of XX% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Generic drugs are bioequivalent of branded drugs in terms of their strength, dosage, safety, quality, performance and efficiency. These drugs are more affordable than their counterparts as the manufacturers do not need to invest in marketing or testing the efficiency and strength of these medicines. Since they are proven to be safe and effective as branded drugs, the demand for generic drugs is escalating in the West African region.
The increasing prevalence of infectious diseases, such as malaria, tuberculosis (TB), and acquired immune deficiency syndrome (AIDS), along with the outbreak of meningitis, polio, pandemic influenza, cholera, measles, hepatitis, tetanus and yellow fever, are positively influencing the demand for generic drugs in the West African region. Moreover, governing authorities of various countries are focusing on investing in the healthcare sectors to reduce the number of deaths caused by the lack of essential drugs. This, in turn, is driving the market of generic drugs in the region. However, the sudden outbreak of the coronavirus disease (COVID-19) and the implementation of lockdown restrictions have hampered the production of generic drugs in the region. The market will experience growth once lockdown restrictions are reduced.
IMARC Group provides an analysis of the key trends in each sub-segment of the West Africa generic drug market, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on segment, therapy area, drug delivery and distribution channel.
Breakup by Segment:
Breakup by Therapy Area:
Breakup by Drug Delivery:
Breakup by Distribution Channel:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2021|
|Segment Coverage||Segment, Therapy Area, Drug Delivery, Distribution Channel, Country|
|Countries Covered||Nigeria, Ghana, Cote d’Ivoire, Senegal, Mali, Others|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option|
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at